PulseAugur
EN
LIVE 13:51:18
中文(ZH) 迪哲医药：与阿斯利康签署授权许可协议

Hits Medicine licenses Shuwozhe® to AstraZeneca for up to $1.9B plus royalties

By PulseAugur Editorial · [1 sources] ·

Hits Medicine has entered into a licensing agreement with AstraZeneca, granting the global rights to develop and commercialize its drug Shuwozhe®. In return, Hits Medicine will receive an upfront payment of $600 million, with potential milestone payments totaling up to $900 million, plus tiered royalties on global sales. This transaction is considered a related-party transaction and requires shareholder approval. AI

IMPACT This deal highlights significant investment and potential in pharmaceutical AI applications, driving innovation in drug development and commercialization.

RANK_REASON Significant licensing deal between two major companies with substantial financial terms. [lever_c_demoted from significant: ic=1 ai=0.4]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Hits Medicine licenses Shuwozhe® to AstraZeneca for up to $1.9B plus royalties

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Significant licensing deal between two major companies with substantial financial terms. [lever_c_demoted from significant: ic=1 ai=0.4]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, funding
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Standard
On-topic for AI-industry coverage; kept in the public index.
Story freshness
74 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Hits Medicine: Signs Licensing Agreement with AstraZeneca

    36氪获悉，迪哲医药公告，公司与AstraZeneca UK Limited（简称“阿斯利康”）签署《许可协议》，授予阿斯利康在全球范围内的独家开发、商业化舒沃哲®的权利。公司将获得阿斯利康支付的一次性、不可返还的首付款6亿美元，最高达4亿美元的临床开发里程碑款项以及最高达5亿美元的销售里程碑款项，此外公司将获得按舒沃哲®全球销售额最高到低双位数的阶梯式比例的特许权使用费。本次交易构成关联交易，但不构成重大资产���组，尚需提交公司股东会审议。

RELATED ENTITIES

RELATED TOPICS